Dizal Pharmaceuticals

This study tests a new drug called DZD8586 combined with standard treatments for diffuse large B-cell lymphoma (DLBCL), a fast-growing blood cancer. About 150 adults with either untreated or relapsed/refractory DLBCL will receive the combination. Researchers will measure how well…

This study tests two experimental drugs, DZD9008 and AZD4205, taken together for advanced non-small cell lung cancer with EGFR mutations that has worsened after standard treatments. About 90 adults will participate to see if the combination is safe and shrinks tumors. The goal is…

This study tests a new combination of two drugs, GW5282 and golidocitinib, for people with T-cell lymphoma. The first part finds the safest dose, and the second part checks if the combo works better than standard chemotherapy. About 165 adults with newly diagnosed or treated lymp…

This study tests a new drug called DZD8586 in adults whose chronic lymphocytic leukemia or small lymphocytic lymphoma has returned or stopped responding to previous treatments. The goal is to see if the drug can shrink or control the cancer and to understand its side effects. Abo…

This study tests a new drug called DZD6008 in people with advanced non-small cell lung cancer that has certain EGFR gene changes. The main goals are to check the drug's safety and how well it shrinks tumors. About 140 adults will take part, and the drug is given by mouth.

This study tests an experimental drug called DZD8586 in adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. Participants must have failed at least one prior treatment and have very low platelet counts.…

This study tests a new drug called golidocitinib against standard treatments for adults with a rare blood cancer (peripheral T-cell lymphoma) that has returned or not improved after at least one prior therapy. About 218 participants will be randomly assigned to receive either gol…

This study tests a new drug called GW5282 in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 203 adults will take part in this early-phase trial.

This early-stage study tests a new drug, DZD6008, in people with advanced non-small cell lung cancer that has a specific EGFR mutation. The main goals are to check the drug's safety and find the right dose. About 190 adults will take part, and researchers will also watch for any …